The Hepatitis D market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis D pipeline products will significantly revolutionize the Hepatitis D market dynamics.
DelveInsight’s “Hepatitis D Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hepatitis D, historical and forecasted epidemiology as well as the Hepatitis D market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hepatitis D market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Hepatitis D market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis D Market Forecast
Some of the key facts of the Hepatitis D Market Report:
The Hepatitis D market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, Tobevibart and elebsiran, an investigational treatment combination developed by Vir Biotechnology for chronic hepatitis D, has received both Breakthrough Therapy Designation from the U.S. FDA and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA). These designations aim to accelerate the development and review of promising therapies that address unmet medical needs and provide potential advantages over existing treatment options.
In November 2024, Following encouraging results from its Phase 2 clinical trial, Vir Biotechnology is preparing to launch its Phase 3 ECLIPSE program in 2025 to evaluate the combination of tobevibart and elebsiran in adults with chronic hepatitis D. If successful, the findings from the two Phase 3 trials could support regulatory approval applications for the treatment. Data from the ongoing Phase 2 SOLSTICE study (NCT05461170) indicate that the combination therapy effectively suppressed the hepatitis delta virus (HDV) and helped normalize a liver damage marker in patients with hepatitis D.
In September 2023, Eiger BioPharmaceuticals decided to halt the Phase III LIMT-2 study evaluating peginterferon lambda in chronic hepatitis D patients. This decision follows a quarterly safety review by the Data Safety Monitoring Board (DSMB), which recommended discontinuation.
In the 7MM, the United States recorded the highest number of diagnosed prevalent cases of Hepatitis D virus in 2023.
In the U.S., males had a higher number of diagnosed prevalent cases of Hepatitis D compared to females in 2023.
In the U.S., the 18–34 age group had the highest number of diagnosed cases of Hepatitis D in 2023.
Key Hepatitis D Companies: Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others
Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others
The Hepatitis D epidemiology based on gender analyzed that Hepatitis D is more prevalent in males as compared to females
Hepatitis D Overview
Hepatitis D (HDV) is a rare but severe liver infection caused by the hepatitis D virus. It occurs only in individuals already infected with hepatitis B (HBV), as HDV requires HBV to replicate. The infection can lead to rapid liver damage, increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. Transmission occurs through contact with infected blood or bodily fluids, often via injection drug use. Currently, no specific antiviral treatment is widely available, but HBV vaccination can help prevent Hepatitis D by preventing HBV infection.
Get a Free sample for the Hepatitis D Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hepatitis-d-market
Hepatitis D Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hepatitis D Epidemiology Segmentation:
The Hepatitis D market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Hepatitis D
Prevalent Cases of Hepatitis D by severity
Gender-specific Prevalence of Hepatitis D
Diagnosed Cases of Episodic and Chronic Hepatitis D
Download the report to understand which factors are driving Hepatitis D epidemiology trends @ Hepatitis D Epidemiological Insights
Hepatitis D Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to get launched during the study period. The analysis covers Hepatitis D market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hepatitis D Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hepatitis D Therapies and Key Companies
HEPCLUDEX (Bulevirtide): Gilead Sciences
Lonafarnib/ Ritonavir: Eiger Biopharmaceuticals
JNJ-73763989: Johnson & Johnson
To know more about Hepatitis D treatment, visit @ Hepatitis D Medications
Hepatitis D Market Drivers
Opioid epidemic causes increase in new Hepatitis B Virus – Hepatitis D infections because of injection drug use and needle sharing
Globally, Hepatitis D infection is reported to be present in approximately 4% to 6% of chronic hepatitis B carriers and the new epidemiology studies suggested that up to 70 million people worldwide may be infected with Hepatitis D
Hepatitis D Market Barriers
Lack of standardization in Hepatitis D testing
Lack of awareness of Hepatitis D
Impact of Hepatitis B Virus / Hepatitis D in progression to cirrhosis
Need of long-lasting and sustained delivery formulations
Scope of the Hepatitis D Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Hepatitis D Therapeutic Assessment: Hepatitis D current marketed and Hepatitis D emerging therapies
Hepatitis D Market Dynamics: Hepatitis D market drivers and Hepatitis D market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hepatitis D Unmet Needs, KOL’s views, Analyst’s views, Hepatitis D Market Access and Reimbursement
Discover more about therapies set to grab major Hepatitis D market share @ Hepatitis D Treatment Landscape
Table of Contents
1. Hepatitis D Market Report Introduction
2. Executive Summary for Hepatitis D
3. SWOT analysis of Hepatitis D
4. Hepatitis D Patient Share (%) Overview at a Glance
5. Hepatitis D Market Overview at a Glance
6. Hepatitis D Disease Background and Overview
7. Hepatitis D Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatitis D
9. Hepatitis D Current Treatment and Medical Practices
10. Hepatitis D Unmet Needs
11. Hepatitis D Emerging Therapies
12. Hepatitis D Market Outlook
13. Country-Wise Hepatitis D Market Analysis (2020–2034)
14. Hepatitis D Market Access and Reimbursement of Therapies
15. Hepatitis D Market Drivers
16. Hepatitis D Market Barriers
17. Hepatitis D Appendix
18. Hepatitis D Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
